REG - Hikma Pharmaceutical - Siggi Olafsson to step down as Chief Executive

Hikma PharmaceuticalsAnnouncement

24/05/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220524:nRSX5177Ma&default-theme=true

RNS Number : 5177M  Hikma Pharmaceuticals Plc  24 May 2022

This announcement contains inside information.

 

London, 24 May 2022 - Hikma Pharmaceuticals PLC (Hikma) today announces that
Siggi Olafsson has resigned as Chief Executive Officer (CEO), and from Hikma's
Board of Directors, to pursue other opportunities.

 

Said Darwazah, Hikma's Executive Chairman and former CEO, will assume all CEO
responsibilities, enabling Hikma to continue delivering its strategy. Siggi
will remain available to the Group until he departs on 24 June 2022.

 

Said will continue to work closely with the Executive Committee, including
Hikma's three divisional presidents, benefiting from their significant
experience and strong management teams. Concurrently, Hikma's Board has
initiated an externally facilitated process to identify a new CEO.

 

Said Darwazah said:

"On behalf of Hikma's Board and the entire Group, I would like to thank Siggi
for his leadership over the past four years. Together with the Executive
Committee, he has worked tirelessly to drive strategic momentum across all
three businesses, especially during the challenging days of the pandemic.
Hikma is on a strong footing and well positioned for future growth, and we
wish Siggi well for the future".

 

Siggi Olafsson said:

"It has been a privilege to work for Hikma, and I am proud of what the entire
team has achieved during my tenure.   I would like to thank the Board for
their confidence in me throughout the past four years. I would also like to
thank my colleagues around the world for their exceptional hard work and
commitment. I believe that Hikma has an exciting future and I look forward to
seeing the business go from strength to strength."

 

-- ENDS -

 

The person responsible for the release of this announcement on behalf of Hikma
is Peter Speirs (Company Secretary).

 

Enquiries:

Hikma (Investors)

 Susan Ringdal                                                              +44 (0)20 7399 2760/ +44 7776 477050

 EVP, Strategic Planning and Global Affairs
 Guy Featherstone                                                           +44 (0)20 3892 4389/ +44 7795 896738

 Senior Investor Relations
 Manager
 Layan Kalisse                                                              +44 (0)20 7399 2788/ +44 7970 709912

 Investor Relations Analyst

 Teneo (Press)

 Charles Armitstead

 Camilla Cunningham                                                         + 44 (0) 7703 330269

                                                                            + 44 (0) 7464 982426

 

 

 

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/stable Fitch)

 

Hikma helps put better health within reach every day for millions of people
around the world. For more than 40 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
the United States (US), the Middle East and North Africa (MENA) and Europe,
and we use our unique insight and expertise to transform cutting-edge science
into innovative solutions that transform people's lives. We're committed to
our customers, and the people they care for, and by thinking creatively and
acting practically, we provide them with a broad range of branded and
non-branded generic medicines. Together, our 8,700 colleagues are helping to
shape a healthier world that enriches all our communities. We are a leading
licensing partner, and through our venture capital arm, are helping bring
innovative health technologies to people around the world. For more
information, please visit: www.hikma.com
(https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2531421-1%26h%3D3823969217%26u%3Dhttp%253A%252F%252Fwww.hikma.com%252F%26a%3Dwww.hikma.com&data=02%7C01%7Csweiss%40Hikma.com%7C4a35048c8c764c63c86308d70efbac9e%7C178c1a723d3c40afbaa754615303bcdc%7C0%7C1%7C636994346427346162&sdata=lHZaoOb0u30Y6re6yfLW1Ar4vvBS%2FnjEUNdB00TBaTI%3D&reserved=0)

©2022 Hikma Pharmaceuticals PLC. All rights reserved.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABCGDUUDDDGDX